Despite the importance of the HER family in the tumorigenesis of GC, anti-EGFR therapies (e.g., cetuximab, panitumumab, gefitinib) have shown limited success in GC clinical trials [9, 10]. The gene discussed is EGFR; the disease is gastric cancer.